期刊文献+

沙利度胺对人鼻咽癌细胞株血管内皮生长因子表达影响的观察 被引量:6

Expressions of VEGF and VEGF-C by thalidomide in human nasopharyngeal carcinoma CNE-2 cells
下载PDF
导出
摘要 目的:探讨沙利度胺对人鼻咽癌细胞株体外生长及对血管内皮生长因子表达的影响。方法:采用MTT法检测沙利度胺对人鼻咽癌细胞增殖的抑制率;RT-PCR和免疫细胞化学方法分别检测沙利度胺作用前后血管内皮生长因子基因和蛋白表达水平的变化。结果:沙利度胺能抑制CNE-2细胞增殖,呈浓度依赖性,当60mg/L沙利度胺作用72h,其抑制率为45.6%;不同浓度沙利度胺作用后VEGFmRNA和VEGF-CmRNA表达均降低,VEGFmRNA下降最明显,P<0.05;蛋白表达与其相应mRNA呈正相关,r值分别为0.959和0.974,P值分别为0.035和0.021。结论:沙利度胺能够抑制CNE-2细胞增殖,其作用机制可能与其下调血管内皮生长因子的表达有关。 OBJECTIVE: To evaluate the effects of thalid- omide on the growth and expressions of vascular endothelial growth factors in human nasopharyngeal carcinoma CNE-2 cells. METHODS: The cell growth inhibition was assessed by MTT-mieroculture tetrazolium assay; VEGF mRNA and VEGF C mRNA and their protein expressions in CNE-2 cells were detected by RT-PCR and immunohistochemistry. RE- SULTS: The growth of CNE-2 cells was inhibited by thalido- mide in a dose-dependent manner, and the inhibitive rate was 45.6% after incubation with 60 mg/L thalidomide for 72 h. The VEGF mRNA and VEGF-C mRNA expression levels in CNE-2 cells were all reduced after the treatment of thalidomide, especially VEGF mRNA. Their protein expression levels were consistent with their mRNA expression levels. CONCLUSION: Thalidomide maybe inhibit the growth of CNE 2 cells by down- regulating VEGF expression. Chin J Cancer Prey Treat ,2008,15(22) : 1706-- 1709
出处 《中华肿瘤防治杂志》 CAS 2008年第22期1706-1709,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 沙利度胺 鼻咽肿瘤/药物疗法 血管内皮生长因子 thalidomide nasopharyngeal neoplasms/drug therapy vascular endothelial growth factor
  • 相关文献

参考文献15

  • 1Palazzi M,Guzzo M, Tomatis S, et al, Improved outcome of na sopharyngeal carcinoma treated with conventional radiotherapy [J]. IntJ RadiatOncolBiolPhys, 2004,60(5):1451-1458.
  • 2张中林,刘志苏,孙权.反应停抗肿瘤作用研究进展[J].肿瘤防治杂志,2005,12(7):555-558. 被引量:2
  • 3Onogawa S, Kitadai Y, Tanaka S, et al. Expression of VEGF-C and VEGF-D at the invasive edge correlate with lymph node metastasis and prognosis of patients with colarectal carcinoma[J]. Cancer Sci, 2004, 95(1): 32-39.
  • 4周哲,谷小虎.原发胃癌中VEGF检测与临床病理因素的相关性研究[J].实用肿瘤学杂志,2006,20(2):103-105. 被引量:15
  • 5Nikiteas N I,Tzanakis N. Vascular endothelial growth factor and endoglin(CD-105) in gastric cancer[J]. Garstric Cancer, 2007,10 ( 1 ) : 12-17.
  • 6Kato Y, Asano K, Mogi T,et al. Clincical significance ofcirculating vascular endothelial growth factor in dogs with mammary gland tumors[J]. Vet Med Sci,2007,69(1) :77-80.
  • 7Folkman J. Tumor angiogenesis: Therapeutic implications[J]. N EnglJ Med, 1971, 285(21): 1182-1186.
  • 8D'Amato R K, Loughman M S, Flynn E. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Aead Sci USA, 1994, 91(9) :4082-4085.
  • 9Sauer H, Gunther J, Hescheler J, et al. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals [J]. Am J Pathol, 2000, 156(1) : 151-158.
  • 10Andr'e L M, Darid R F, Bronya S, et al. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro [J]. J Neuro Oncol, 1999, 43(2): 109-114.

二级参考文献53

共引文献32

同被引文献70

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部